Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB-300
- Development stage
- Discontinued
- Lead developer
- HOOKIPA Pharma
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
**HB-300** is an investigational, alternating two-vector arenaviral cancer vaccine regimen developed by HOOKIPA Pharma for metastatic castration-resistant prostate cancer. It comprises the intravenously administered replicating vectors HB-302, based on Pichinde virus, and HB-301, based on lymphocytic choriomeningitis virus; both encode the prostate cancer-associated self-antigens prostatic acid phosphatase and prostate-specific antigen. The regimen is intended to generate strong antigen-specific CD8-positive T-cell responses and antitumor immunity. ([ascopubs.org](https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2023.41.16_suppl.TPS5108))
- Other names
- HB-302/HB-301 alternating 2-vector therapyPAP/PSA-expressing arenaviral vectors HB-302/HB-301
02
Targets
P fimbriae
Beyond the preview
Go deeper on HB-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB-300.